2017
DOI: 10.12788/jcso.0326
|View full text |Cite
|
Sign up to set email alerts
|

Physician attitudes and prevalence of molecular testing in lung cancer

Abstract: Background EGFR mutations and EML4-ALK rearrangements are key therapeutic targets in nonsquamous non-small-cell lung carcinoma (nsNSCLC). Current guidelines recommend testing all patients with advanced nsNSCLC (stages IIIB and IV). Objective To evaluate physician attitudes about molecular testing for nsNSCLC and to determine the rate of testing, the effect of biopsy sample size, and prevalence of driver mutations . Materials and methods In this retrospective study, 206 cases of advanced nsNSCLC were identified… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 28 publications
0
0
0
Order By: Relevance